UPDATE: Affy Closes Down 36 Percent Following Revenue Warning | GenomeWeb

This story has been updated from a previous version.

NEW YORK, June 12 – Affymetrix stock plunged  $14.94, or 36 percent, to close at $26.01 on Tuesday, following an announcement late on Monday that the company was slashing its second-quarter revenue expectations due to a drop in demand for the company’s gene chips and spot arrayers.

The company said its revenues for the quarter would total between $44 million and $50 million rather than $56 million to $58 million as previously expected.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.